RSV and COVID-19 vaccines: Why are we still underestimating their impact?

Written by The Life Science Feed Editorial Team · Published 8 September 2026 · Edited by William Lopes

> Respiratory syncytial virus (RSV) and COVID-19 continue to exert substantial pressure on healthcare systems, driving hospitalisations and mortality across age groups. Effective prevention remains paramount to alleviate this burden and protect at-risk individuals. Vaccination stands as a cornerstone of this preventative approach.

KEY TAKEAWAYS

- The Pivot: Proactive vaccination against RSV and COVID-19 is now a key strategy for reducing severe respiratory illness.
- The Data: Specific efficacy data varies by vaccine and population, but overall, these vaccines significantly reduce hospitalisation and death.
- The Action: Clinicians should advocate for and facilitate uptake of recommended RSV and COVID-19 vaccines, particularly in high-risk groups.

Respiratory infections, particularly those caused by RSV and SARS-CoV-2, represent a persistent challenge in public health. These viruses contribute to significant morbidity and mortality, especially among infants, older adults, and individuals with underlying health conditions. The clinical presentation can range from mild upper respiratory symptoms to severe pneumonia, bronchiolitis, and acute respiratory distress syndrome, often necessitating hospitalisation and intensive care. The economic impact, alongside the human cost, highlights the urgent need for robust preventative measures.

The immune response to both RSV and SARS-CoV-2 can be complex, with natural infection not always conferring durable or complete protection against subsequent exposures. This immunological reality, coupled with the viruses' propensity for antigenic drift (in the case of SARS-CoV-2) or the unique challenges of infant immunity (for RSV), necessitates ongoing efforts to develop and deploy effective vaccines. The goal is to prime the immune system to mount a rapid and effective response upon exposure, thereby preventing severe disease outcomes.

The Mechanisms of Protection

Vaccines against RSV typically target the fusion (F) protein, a highly conserved surface glycoprotein essential for viral entry into host cells. By inducing antibodies against this protein, vaccines aim to neutralise the virus and prevent infection or reduce disease severity. Some RSV vaccines employ a prefusion conformation of the F protein, which is more immunogenic and elicits a stronger protective antibody response. This approach has shown particular promise in protecting infants through maternal vaccination, where antibodies are transferred across the placenta, offering passive immunity during the vulnerable first months of life. For older adults, direct vaccination stimulates their own immune

systems to produce protective antibodies, bolstering defenses against a virus that can cause severe lower respiratory tract disease.

COVID-19 vaccines, predominantly mRNA-based or viral vector platforms, focus on the spike (S) protein of SARS-CoV-2. This protein mediates viral attachment and entry into human cells. Vaccination induces both humoral immunity, through the production of neutralising antibodies, and cellular immunity, involving T-cell responses. These T-cells play a critical role in clearing infected cells and limiting disease progression. The rapid development and deployment of these vaccines during the pandemic demonstrated their capacity to significantly reduce symptomatic infection, severe illness, hospitalisation, and death. Ongoing vaccine updates address emerging variants, maintaining a degree of protection against evolving strains. Clinicians often find the Oxford Handbook of Infectious Diseases and Microbiology a useful reference for understanding these complex viral mechanisms and vaccine strategies.

Targeting Vulnerable Populations

For RSV, infants represent a particularly vulnerable group, with bronchiolitis and pneumonia being common causes of hospitalisation in the first year of life. Maternal vaccination, administered during pregnancy, allows for the transfer of protective antibodies to the fetus, providing passive immunity at birth, which is vital for their health. This strategy directly addresses the challenge of vaccinating very young infants, whose immune systems are still developing. Older adults, especially those with chronic cardiopulmonary conditions or immunocompromise, also face a high risk of severe RSV disease. Vaccines tailored for this demographic aim to prevent the severe lower respiratory tract infections that can lead to prolonged hospital stays and increased mortality. The burden of RSV on paediatric and geriatric populations is substantial, making targeted vaccination a public health imperative.

COVID-19 vaccination strategies have similarly prioritised vulnerable populations. Older adults, individuals with comorbidities such as diabetes, heart disease, chronic lung disease, and immunocompromised patients consistently demonstrate higher risks of severe outcomes, including hospitalisation, intensive care unit admission, and death. Vaccination in these groups has been shown to mitigate these risks substantially. The coadministration of COVID-19 and influenza vaccines has also been explored, demonstrating safety and efficacy, which simplifies vaccine delivery and improves uptake. Our previous coverage on coadministration of COVID-19 and flu shots highlighted these benefits.

The Broader Impact of Vaccination

Beyond direct protection for vaccinated individuals, widespread vaccination against RSV and COVID-19 contributes to broader public health benefits. Reducing the incidence of severe disease in vaccinated individuals lessens the overall circulation of the virus within communities. This phenomenon, often referred to as herd immunity or community protection, indirectly safeguards those who cannot be vaccinated or who may not mount a strong immune response. For RSV, reducing viral load in the community can protect vulnerable infants and immunocompromised individuals who rely on reduced exposure for their safety. Similarly, for COVID-19, high vaccination rates help to prevent surges in cases that can overwhelm healthcare infrastructure, ensuring resources remain available for all patients needing care. The impact on hospital capacity and staffing during peak respiratory seasons is a significant consideration for healthcare systems across Europe.

The economic benefits of preventing severe respiratory disease are also considerable. Reduced hospitalisations, fewer intensive care admissions, and decreased need for prolonged medical care translate into substantial cost savings for

healthcare systems. Productivity losses due to illness and caregiving responsibilities are also mitigated. These economic arguments further strengthen the case for proactive vaccination policies. But the primary driver remains the reduction of human suffering and the preservation of life. The ongoing evolution of SARS-CoV-2, with new variants emerging, means that continuous monitoring and adaptation of vaccine strategies are necessary. This includes considering updated vaccine formulations to maintain protection against circulating strains. The effectiveness of public health measures, including vaccination, in reducing incidence has been well-documented.

Challenges and Future Directions

Despite the clear benefits, challenges remain in optimising vaccination strategies. Vaccine hesitancy, logistical hurdles in distribution, and ensuring equitable access across diverse populations are persistent issues. Effective public health campaigns are essential to communicate the safety and efficacy of these vaccines, addressing misinformation and building trust within communities. The integration of RSV and COVID-19 vaccination into routine immunisation schedules, alongside influenza vaccination, could streamline delivery and improve uptake. This requires careful planning and coordination between public health bodies and primary care providers.

Future research will continue to refine vaccine technologies, aiming for broader and more durable protection against a wider array of respiratory pathogens. Combination vaccines, offering protection against multiple viruses in a single shot, represent an attractive future direction, potentially simplifying immunisation schedules and improving adherence. The development of pan-respiratory virus vaccines remains a long-term goal, offering the potential for comprehensive protection against seasonal threats. The ongoing surveillance of viral epidemiology and vaccine effectiveness is essential to adapt strategies as pathogens evolve. The open-label design of many early vaccine rollouts is an obvious caveat, but real-world data has largely confirmed the benefits observed in controlled settings. The question remains how best to integrate these newer vaccines into existing primary care workflows to maximise their impact.

CLINICAL IMPLICATIONS

The imperative to vaccinate against RSV and COVID-19 is clear. Clinicians must actively engage in discussions with patients, particularly those in high-risk categories, about the benefits of these preventative measures. It is not merely about individual protection, but about contributing to community-wide resilience against seasonal and emergent respiratory threats.

For healthcare systems, the proactive deployment of these vaccines offers a tangible strategy to alleviate the annual strain on hospital beds and intensive care units. Reducing severe cases frees up resources for other critical care needs, a lesson painfully learned during the pandemic. The cost-effectiveness of preventing hospitalisations far outweighs the investment in vaccination programs.

The industry must continue to innovate, developing broader and more accessible vaccine formulations. Simplified administration, perhaps through combination vaccines, will be key to improving uptake and adherence in busy primary care settings. The focus should remain on durable protection against evolving viral strains.

Patients, especially those with chronic conditions or advanced age, stand to gain significantly from these vaccinations. The reduction in severe illness, hospitalisation, and mortality translates directly into preserved quality of life and reduced healthcare burden. This is a straightforward clinical win.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Bourdeau M, Vadlamudi NK, Bastien N, et al. Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic. JAMA Netw Open. 2023;6(10):e2336863. doi:10.1001/jamanetworkopen.2023.36863
2. 2. Wildenbeest JG, Bont L, Cianci D, et al. Dynamics of RSV hospitalization rates in d 2-year-old children between 2020-2023 in Europe. Eur J Pediatr. 2025;184(10):615. doi:10.1007/s00431-025-06218-1
3. 3. Theakston C, Napier M, Brassel S, et al. A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan. Expert Rev Vaccines. 2025;24(1):633-643. doi:10.1080/14760584.2025.2536092
4. 4. Harrison C, Brassel S, Chowdhury S, et al. The broader socio-economic value of adult respiratory disease vaccinations in the UK - results from a benefit cost analysis. Expert Rev Vaccines. 2025;24(1):644-655. doi:10.1080/14760584.2025.2536093
5. 5. Zoubeir B, Hind B, Sonia D, et al. Circulation of Influenza and Other Respiratory Viruses in Tunisia, 2022-2023 Season. Influenza Other Respir Viruses. 2026;20(5):e70199. doi:10.1111/irv.70199
6. 6. Garcia-Rodriguez J, Janvier F, Kill C. Key Insights into Respiratory Virus Testing: Sensitivity and Clinical Implications. Microorganisms. 2025;13(1). doi:10.3390/microorganisms13010063

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com